• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

年龄校正后的Charlson合并症指数作为早期胃癌内镜下黏膜下剥离术后患者预后因素的影响。

The impact of the age-adjusted Charlson comorbidity index as a prognostic factor in patients with early gastric cancer after endoscopic submucosal dissection.

作者信息

Shi Xiao, Li Ruibo, Shi Xiaoyi, Yan Yuxing, Gong Aixia

机构信息

Department of Gastroenterology, First Affiliated Hospital, Dalian Medical University, Dalian, China.

Department of Gastroenterology, the Second People's Hospital of Liaocheng, Liaocheng, China.

出版信息

Scand J Gastroenterol. 2025 Feb;60(2):136-142. doi: 10.1080/00365521.2024.2449072. Epub 2025 Jan 8.

DOI:10.1080/00365521.2024.2449072
PMID:39773271
Abstract

BACKGROUND

The Charlson Comorbidity Index (CCI) and prognostic nutritional index (PNI) have proven to be valuable tools in predicting prognosis based on comorbidities and nutritional status in the context of surgical procedures and endoscopic resections. The age-Adjusted CCI (ACCI) has also shown utility in surgical settings, but its application to early gastric cancer (EGC) remains unexplored. Consequently, we aimed at clarifying the prognostic factors for EGC treated with endoscopic submucosal dissection (ESD).

METHODS

Patients who underwent ESD for EGC at the First Affiliated Hospital of Dalian Medical University from January 2015 to February 2023 were included. The overall survival (OS) and prognostic predictive ability were evaluated based on patients and lesion characteristics.

RESULTS

During a median follow-up period of 50 months, 15 patients died, but none from the gastric cancer. The 5-year survival rate was 90.0%. In univariate and multivariate analyses, a high ACCI (>4.5) was the only significant prognostic factor (Hazard ratio, 27.78; 95% confidence interval, 3.62-213.40;  < 0.01). The 5-year survival rates for patients with low ACCI (<4.5) and high ACCI were 98.9% and 72.9%, respectively ( < 0.01).

CONCLUSIONS

A high ACCI is a significant prognostic indicator for 5-year survival and the risk of mortality caused by other comorbidities. EGC suitable for ESD is unlikely to serve as a prognostic factor, and ACCI should be considered as an important reference when considering additional surgical procedures in high-ACCI patients after ESD with endoscopic curability (eCura) C-2 for EGC.

摘要

背景

在外科手术和内镜切除的背景下,查尔森合并症指数(CCI)和预后营养指数(PNI)已被证明是基于合并症和营养状况预测预后的有价值工具。年龄调整后的CCI(ACCI)在外科手术环境中也显示出实用性,但其在早期胃癌(EGC)中的应用仍未得到探索。因此,我们旨在阐明内镜黏膜下剥离术(ESD)治疗EGC的预后因素。

方法

纳入2015年1月至2023年2月在大连医科大学附属第一医院接受ESD治疗EGC的患者。根据患者和病变特征评估总生存期(OS)和预后预测能力。

结果

在中位随访期50个月期间,15例患者死亡,但均非死于胃癌。5年生存率为90.0%。在单因素和多因素分析中,高ACCI(>4.5)是唯一显著的预后因素(风险比,27.78;95%置信区间,3.62 - 213.40;P < 0.01)。低ACCI(<4.5)和高ACCI患者的5年生存率分别为98.9%和72.9%(P < 0.01)。

结论

高ACCI是5年生存率和其他合并症导致死亡风险的显著预后指标。适合ESD的EGC不太可能作为预后因素,在EGC内镜治愈性(eCura)C - 2级ESD后考虑对高ACCI患者进行额外手术时,应将ACCI视为重要参考。

相似文献

1
The impact of the age-adjusted Charlson comorbidity index as a prognostic factor in patients with early gastric cancer after endoscopic submucosal dissection.年龄校正后的Charlson合并症指数作为早期胃癌内镜下黏膜下剥离术后患者预后因素的影响。
Scand J Gastroenterol. 2025 Feb;60(2):136-142. doi: 10.1080/00365521.2024.2449072. Epub 2025 Jan 8.
2
Impact of the Charlson comorbidity index and prognostic nutritional index on prognosis in patients with early gastric cancer after endoscopic submucosal dissection.探讨 Charlson 合并症指数和预后营养指数对内镜黏膜下剥离术后早期胃癌患者预后的影响。
Dig Endosc. 2018 Sep;30(5):616-623. doi: 10.1111/den.13051. Epub 2018 Apr 11.
3
High-Risk Comorbidity Influences Prognosis in Early Gastric Cancer after Noncurative Endoscopic Submucosal Dissection: A Retrospective Study.高危合并症对非治愈性内镜黏膜下剥离术后早期胃癌预后的影响:一项回顾性研究。
Dig Dis. 2021;39(2):96-105. doi: 10.1159/000510115. Epub 2020 Jul 14.
4
Predictive Factors for Short-Term Survival after Non-Curative Endoscopic Submucosal Dissection for Early Gastric Cancer.早期胃癌内镜黏膜下剥离术非治愈性治疗后短期生存的预测因素。
Digestion. 2021;102(4):630-639. doi: 10.1159/000510165. Epub 2020 Sep 15.
5
Modified Charlson comorbidity index of long-term, non-gastric cancer mortality in patients with early gastric cancer: a multicenter retrospective study.早期胃癌患者长期非胃癌死亡的改良Charlson合并症指数:一项多中心回顾性研究
World J Surg Oncol. 2025 Mar 24;23(1):100. doi: 10.1186/s12957-025-03741-1.
6
The impact of the age-adjusted Charlson comorbidity index as a prognostic factor for endoscopic papillectomy in ampullary tumors.年龄调整 Charlson 共病指数作为壶腹肿瘤内镜乳头切除术预后因素的影响。
J Gastroenterol. 2022 Mar;57(3):199-207. doi: 10.1007/s00535-022-01853-z. Epub 2022 Jan 30.
7
Long-term outcomes and prognostic factors with non-curative endoscopic submucosal dissection for gastric cancer in elderly patients aged ≥ 75 years.≥75 岁老年患者行非治愈性内镜黏膜下剥离术治疗胃癌的长期预后及相关因素。
Gastric Cancer. 2019 Jul;22(4):838-844. doi: 10.1007/s10120-018-00913-9. Epub 2018 Dec 17.
8
Endoscopic submucosal dissection versus surgery in elderly patients with early gastric cancer of relative indication for endoscopic resection.内镜黏膜下剥离术与手术治疗相对适应证的老年早期胃癌患者。
Dig Endosc. 2022 Mar;34(3):497-507. doi: 10.1111/den.14105. Epub 2021 Sep 16.
9
Endoscopic Submucosal Dissection for Early Gastric Cancer in Patients Aged 85 Years Old or Older Is Associated with a Good Prognosis Compared to Conservative Treatment without Any Invasive Procedure.高龄(≥85 岁)患者早期胃癌行内镜黏膜下剥离术与不进行任何有创操作的保守治疗相比,预后较好。
Digestion. 2022;103(5):386-396. doi: 10.1159/000525422. Epub 2022 Jul 21.
10
Effect of Charlson Comorbidity Index and Treatment Strategy on Survival of Elderly Patients After Endoscopic Submucosal Dissection for Gastric Adenocarcinoma: A Multicenter Retrospective Study.高龄患者胃腺癌内镜黏膜下剥离术后生存的 Charlson 共病指数及治疗策略的影响:一项多中心回顾性研究。
Front Public Health. 2022 Jan 3;9:803113. doi: 10.3389/fpubh.2021.803113. eCollection 2021.

引用本文的文献

1
Trends and outcomes for patients receiving neoadjuvant therapy for stage I to III gastric gastrointestinal stromal tumors.接受新辅助治疗的Ⅰ至Ⅲ期胃胃肠道间质瘤患者的趋势与预后
J Gastrointest Surg. 2025 Aug;29(8):102117. doi: 10.1016/j.gassur.2025.102117. Epub 2025 Jun 16.